A fast, bedside test to tell Type 1 vs Type 2 heart attacks
Official title: Point of Care Differential Scanning Calorimetry
Funded at Creosalus, INC. · NIH-11316332 · Data updated 2026-11-12
A new DSC-based diagnostic tool aims to quickly tell whether a chest-pain patient has a Type 1 heart attack (blood clot–related) or Type 2, to guide safer treatment.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Creosalus, INC. NIH-funded |
| Lab location | 1 site (Louisville, United States) |
| Project start | September 1, 2026 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $314,359 |
| NIH project number | 1R41EB038861-01 |
| Project ID | NIH-11316332 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients presenting to the hospital with chest pain and suspected myocardial infarction.
✕Less likely to help
Patients without suspected MI or with non-cardiac chest pain may not benefit from this diagnostic approach.
What this research studies
This project develops a point-of-care diagnostic system using differential scanning calorimetry to differentiate Type 1 and Type 2 myocardial infarctions in patients presenting with chest pain. The goal is to reduce misdiagnosis and avoid dangerous treatments by providing rapid, clinically actionable results. It involves collaboration between CreoSalus, Inc. and university researchers to translate a patented DSC algorithm into a usable clinical test. The study focuses on translating laboratory methods into a fast diagnostic workflow that can be used at the bedside or in the emergency department. Participation would involve patients with suspected MI to provide data for validating the DSC-based criteria.
Why it matters
Potential benefit: If successful, patients with heart attacks could receive the right treatment faster, reducing risks from unnecessary therapies and improving outcomes.
How similar studies have gone: Related DSC-based approaches have shown promise in identifying myocardial injury, but this project aims to translate to a rapid, point-of-care format.
Where this research is happening
-
Creosalus, INC.
Louisville, United States Active
Researchers
- Principal investigator: Wilson, Michael — Creosalus, INC.
- Study coordinator: Wilson, Michael
Related research
Other NIH-funded projects on the same topics.
-
Comparing two ways to deliver medicine directly into the brain for recurrent high‑grade glioma
This compares a new porous brain infusion catheter plus planning software to a standard end‑port catheter to deliver more medication into tumors for people with recurrent grade 3–4 glioma.
-
Improving drug delivery for recurrent glioblastoma patients
This study is testing a new way to deliver cancer treatments directly to glioblastoma tumors using a special catheter, and it's for patients who are looking for better options to fight this tough type of brain cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.